Furthermore, BAL flow cytometry identifies CD8+ T lymphocytes as protective mediators against pulmonary fibrosis and mortality, highlighting their potential as prognostic biomarkers of disease severity in HP and identifying them as promising targets for therapeutic strategies aimed at mitigating fibrosis progression in interstitial lung disease. Here, CD8A is linked to hypersensitivity pneumonitis.